Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal

NCT01843452 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Poor recruitment

Conditions

Carcinoma of Anal Canal

Interventions

RADIATION: RADIOTHERAPY
BIOLOGICAL: PANITUMUMAB
DRUG: MITOMYCIN
DRUG: CAPECITABINE

Sponsor

Centre Hospitalier Universitaire Vaudois